Parabricks
Parabricks provides GPU-accelerated genomics software for secondary analysis, reimplementing BWA-MEM, GATK, and DeepVariant on NVIDIA hardware. Now operating as NVIDIA Clara Parabricks, it serves research institutions, hospitals, clinical labs, and pharmaceutical companies.
- Company typePrivate
- Founded2016
- HeadquartersAnn Arbor, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Parabricks does
Parabricks develops GPU-accelerated genomics software that performs secondary analysis of next-generation sequencing data, replacing CPU-based implementations of standard bioinformatics tools with parallelized versions that run on NVIDIA hardware. The platform delivers GPU-optimized implementations of the three dominant secondary analysis components — BWA-MEM for sequence alignment, GATK for variant calling, and Google's DeepVariant for deep-learning-based variant calling — and ships a broader suite of 23 accelerated tools organized into six pre-configured pipelines for whole-genome and exome sequencing. The company claims over 100x faster whole-genome sequencing analysis with 50% lower compute cost relative to traditional CPU-based workflows.
The platform is sold primarily to academic research centers, hospitals, clinical laboratories, pharmaceutical companies, and population-genomics initiatives, with documented use cases spanning cancer and rare-disease research, rapid NICU diagnosis, and large-scale biobank analysis. Distribution and commercialization now run through NVIDIA's enterprise sales channels and developer portal under the NVIDIA Clara Parabricks brand, following Parabricks' acquisition by NVIDIA. Earlier-stage non-dilutive capital came from National Science Foundation SBIR awards totaling approximately $1.37M across 2016 and 2018, along with an early investment from the Michigan Biomedical Venture Fund.
The business model is enterprise software licensing bundled into NVIDIA's healthcare and life sciences portfolio, with downloads and trial access available through NVIDIA's developer portal. Specific pricing, contract terms, and stand-alone revenue are not publicly disclosed, and Parabricks does not report as a separate entity post-acquisition.
Parabricks firmographics
Firmographics- Name
- Parabricks
- Website
- https://parabricks.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Parabricks provides GPU-accelerated genomics software for secondary analysis, reimplementing BWA-MEM, GATK, and DeepVariant on NVIDIA hardware. Now operating as NVIDIA Clara Parabricks, it serves research institutions, hospitals, clinical labs, and pharmaceutical companies.
- Ownership category
- akta.pro rank
Parabricks industry classification
Industry- Product category
- Genomics Bioinformatics Software
- NAICS
- Computer Systems Design and Related Services (5415), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Processing & Data Preparation (7374)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where Parabricks is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Markets served
Parabricks business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- GPU-Accelerated Genomics Software Licensing: Parabricks is distributed as part of NVIDIA's healthcare and life sciences software portfolio, likely through enterprise licensing arrangements for genomic research institutions, hospitals, and pharmaceutical companies.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Parabricks product offering
Product offeringCore offering
Parabricks provides GPU-accelerated genomics software for the secondary analysis of sequencing data, delivering optimized CUDA implementations of industry-standard bioinformatics tools (BWA-MEM, GATK, DeepVariant) packaged into 23 accelerated tools and six pre-configured pipelines for whole-genome and exome sequencing workflows. The product enables analysis of a whole human genome in under an hour, compared to days on traditional CPU infrastructure, at roughly 50% lower compute cost.
Product overview
NVIDIA Parabricks is a single, unified genomics software platform that provides GPU-accelerated implementations of industry-standard bioinformatics tools including BWA-MEM (sequence alignment), GATK (variant calling), and DeepVariant (deep learning variant caller). The platform offers 23 accelerated tools organized into six pre-configured pipelines for whole-genome and exome sequencing workflows. Parabricks operates as a standalone product within NVIDIA's Clara healthcare division, delivering over 100x speed improvement for whole-genome sequencing analysis while reducing compute costs by 50 percent.
Differentiator
Problem solved
Functional benefit
Products and services
- NVIDIA Parabricks
Quantifiable outcome
- Over 100x faster whole-genome sequencing analysis compared to CPU-based methods
- +1 more outcomes
Companies that use Parabricks
Customer profileSegments3 records
Ideal customer profiles3 records
Parabricks technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature7 records
Parabricks partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIAcoreParabricks was acquired by NVIDIA and integrated into NVIDIA's healthcare and life sciences platform. The technology is now part of NVIDIA Clara Parabricks, combining GPU-accelerated genomic analysis with NVIDIA's broader AI and computing infrastructure for healthcare applications.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Parabricks competitors and assessment
Company assessmentRegional players
- Strand Life Sciences: Strand Life Sciences provides bioinformatics and clinical genomics interpretation platforms, with comparable workflows for variant calling and clinical reporting, primarily serving the Indian and emerging markets.
Emerging players
- Lifebit: Lifebit offers a federated genomics data and analytics platform for clinical and pharmaceutical customers, with overlapping use cases in population genomics and clinical interpretation.
- Form Bio (subsidiary of Colossal Biosciences): Form Bio offers a cloud-based bioinformatics platform with pre-configured pipelines for genomic analysis, competing in adjacent developer and clinical research segments.
- BC Platforms: BC Platforms provides genomic data management and analytics infrastructure for precision medicine and biobanking, competing for similar enterprise genomics analysis workloads.
Direct peers
- Edico Genome (now part of Illumina): Edico Genome developed DRAGEN, the FPGA-accelerated genomics analysis platform acquired by Illumina — a direct competitor to Parabricks' GPU-accelerated secondary analysis offering.
- Sentieon: Sentieon offers highly optimized secondary analysis pipelines (DNAscope, TNscope) for accurate and fast variant calling, directly competing with Parabricks' GPU-accelerated GATK and DeepVariant implementations.
- Illumina DRAGEN: Illumina's DRAGEN platform provides hardware-accelerated (FPGA) secondary analysis for genomic sequencing, directly competing with Parabricks on speed, accuracy, and cost for clinical and research sequencing workflows.
- Google DeepVariant: Google's open-source DeepVariant uses deep learning for variant calling — one of the core tools Parabricks accelerates. DeepVariant represents the primary open-source benchmark Parabricks is measured against.
Broad incumbents
- Velsera (formerly Seven Bridges): Velsera offers a genomics informatics platform with secondary and tertiary analysis pipelines, serving pharma, clinical, and research customers in a similar segment to Parabricks.
- DNAnexus: DNAnexus provides a cloud-based genomics data analysis and collaboration platform used by large clinical and research institutions, overlapping with Parabricks on enterprise genomic workflow deployment.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights5 records
Customer concentration
Parabricks social profiles
Digital presenceParabricks financial estimates
Financial estimateRevenue estimate
Valuation estimate
Parabricks leadership team
Management profileNumber of profiles
Profiles1 record
Parabricks funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Parabricks M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Parabricks
What does Parabricks do?
Parabricks provides GPU-accelerated genomics software for the secondary analysis of sequencing data, delivering optimized CUDA implementations of industry-standard bioinformatics tools (BWA-MEM, GATK, DeepVariant) packaged into 23 accelerated tools and six pre-configured pipelines for whole-genome and exome sequencing workflows. The product enables analysis of a whole human genome in under an hour, compared to days on traditional CPU infrastructure, at roughly 50% lower compute cost.
Is Parabricks a public or private company?
Parabricks is a private company. It is classified as corporate owned and is currently acquired.
When was Parabricks founded?
Parabricks was founded in 2016. It employs 1 to 10 people.
Where is Parabricks based?
Parabricks is headquartered in Ann Arbor, United States, in the North America region.
How does Parabricks make money?
One revenue line is on record: GPU-Accelerated Genomics Software Licensing.
Who are Parabricks's main competitors?
Strand Life Sciences is listed as a regional player. Emerging players are Lifebit, Form Bio (subsidiary of Colossal Biosciences) and BC Platforms. Direct peers are Edico Genome (now part of Illumina), Sentieon, Illumina DRAGEN and Google DeepVariant. Broad incumbents are Velsera (formerly Seven Bridges) and DNAnexus.
Does Parabricks have an API?
No public API is recorded for Parabricks.
What industry is Parabricks in?
Parabricks's product category is Genomics Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5415 and its SIC code is 7372.